Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID.

Date publication

avril 2026

Journal

United European gastroenterology journal

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine

Tous les auteurs :
Calméjane L, Reenaers C, Gay C, Amiot A, Nuzzo A, Vuitton L, Atanasiu C, Stefanescu C, Altwegg R, Guillo L, Serrero M, Bouguen G, Nachury M, Cosquer GL, Roblin X, Abitbol V, Hammoudi N, Simon M, Fumery M, Savoye G, Benezech A, Cavicchi M, Charkaoui M, Buisson A, Caron B, Coffin B, Geyl S, Goutorbe F, Hupé M, Vidon M, Laharie D, Kirchgesner J, Uzzan M,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41880233

Résumé

Vedolizumab has become the preferred first-line advanced therapy in ulcerative colitis (UC). However, the optimal second-line treatment following vedolizumab failure remains unclear. We aimed to evaluate the effectiveness and safety of second-line therapies after first-line vedolizumab.

Mots clés

anti‐TNF, biologics, infliximab, treatment sequencing, ulcerative colitis, ustekinumab, vedolizumab

Référence

United European Gastroenterol J. 2026 04;14(3):e70203